This company is no longer active
Gemini Therapeutics Past Performance
How has Gemini Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GMTX is currently unprofitable.
Growing Profit Margin: GMTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GMTX is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.
Accelerating Growth: Unable to compare GMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: GMTX has a negative Return on Equity (-41.52%), as it is currently unprofitable.